Stephen T. Schlachter
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)University of Colorado Boulder(US)Pear Therapeutics (United States)(US)Healthwise(US)Cellerant Therapeutics (United States)(US)Edgewise Therapeutics (United States)University of California, Davis(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Organophosphorus compounds synthesis, Bone health and treatments, Phosphorus compounds and reactions, Epigenetics and DNA Methylation
Most-Cited Works
- → A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma(2016)316 cited
- → 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma(2019)202 cited
- → Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors(2012)184 cited
- → Pyrazoline bisphosphonate esters as novel antiinflammatory and antiarthritic agents(1993)116 cited
- → Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)(2018)110 cited
- DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.